

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The Phase III randomized INO-VATE trial demonstrated a modest 2-year overall survival advantage with \_\_\_\_\_ compared to standard chemotherapy for patients with relapsed/refractory acute lymphoblastic leukemia.
  - Inotuzumab ozogamicin
  - Obinutuzumab
  - Elotuzumab
- The Phase III SWOG-S0777 trial evaluating lenalidomide and dexamethasone with or without bortezomib for patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) demonstrated a statistically significant improvement in \_\_\_\_\_ with the addition of bortezomib.
  - Progression-free survival
  - Overall survival
  - Overall response rate
  - Both a and c
  - All of the above
- Results from the registrational Phase II CheckMate 205 trial evaluating the efficacy of nivolumab in the cohort of patients with relapsed/refractory classical Hodgkin lymphoma demonstrated a high response rate for patients after ASCT and brentuximab vedotin.
  - True
  - False
- \_\_\_\_\_ is FDA approved as a single agent for the treatment of multiple myeloma in patients who have received at least 3 prior therapies.
  - Elotuzumab
  - Panobinostat
  - Daratumumab
  - Ixazomib
  - Both b and c
  - All of the above
  - None of the above
- The results of the Phase III POLLUX trial evaluating lenalidomide and dexamethasone with or without daratumumab for patients with relapsed/refractory multiple myeloma demonstrated \_\_\_\_\_ with the addition of daratumumab.
  - A statistically significant improvement in progression-free survival
  - An increase in the rate of infusion-related reactions
  - Both a and b
- Recently the FDA approved \_\_\_\_\_, a Bcl-2 inhibitor, for the treatment of chronic lymphocytic leukemia in patients harboring the 17p deletion chromosomal abnormality who have received at least 1 prior therapy.
  - Obinutuzumab
  - Acalabrutinib
  - Venetoclax
  - Ibrutinib
- In the Phase II ECOG-E2408 trial of bendamustine/rituximab (BR) with or without bortezomib (V) followed by rituximab with or without lenalidomide for patients with previously untreated high-risk follicular lymphoma, the complete remission rate with BVR induction therapy was \_\_\_\_\_ to that with BR alone.
  - Significantly superior
  - Equivalent
  - Inferior
- Atrial fibrillation is an adverse event that is associated with ibrutinib therapy for patients with chronic lymphocytic leukemia.
  - True
  - False
- \_\_\_\_\_ is a novel FLT3 inhibitor that is currently being investigated in the treatment of FLT3 mutation-positive acute myeloid leukemia.
  - Midostaurin
  - Acalabrutinib
  - Sorafenib
  - Crenolanib
  - All of the above
  - All except b
- Daids and colleagues demonstrated a response rate higher than 30% with the administration of a repeated high dose of the CTLA-4 inhibitor ipilimumab to patients with relapsed hematologic cancer after allogeneic stem cell transplant.
  - True
  - False